



**Smartphone Clip-On Instrument and Microfluidic Processor
for Rapid Sample-to-Answer Detection of Zika Virus in
Whole Blood Using Spatial RT-LAMP**

Journal:	<i>Analyst</i>
Manuscript ID	AN-ART-03-2022-000438.R1
Article Type:	Paper
Date Submitted by the Author:	08-Jun-2022
Complete List of Authors:	Jankelow, Aaron; University of Illinois at Urbana-Champaign, Bioengineering Lee, Hankeun; University of Illinois at Urbana-Champaign Wang, Weijing; University of Illinois at Urbana-Champaign Hoang, Trung-Hieu; University of Illinois at Urbana-Champaign Bacon, Amanda; University of Illinois at Urbana-Champaign Sun, Fu; University of Illinois at Urbana-Champaign College of Engineering, Chae, Seol; University of Illinois at Urbana-Champaign Kindratenko, Victoria; University of Illinois at Urbana-Champaign, Bioengineering Koprowski, Katherine; University of Illinois at Urbana-Champaign Stavins, Robert; University of Illinois at Urbana-Champaign, Mechanical Engineering Ceriani, Dylann; Gener8 LLC Engelder, Zachary; Gener8 LLC King, William; University of Illinois at Urbana-Champaign, Mechanical Science and Engineering Do, Minh; University of Illinois at Urbana-Champaign Bashir, Rashid; University of Illinois at Urbana-Champaign, Micro and Nanotechnology Laboratory Valera, Enrique; University of Illinois at Urbana-Champaign, Department of Bioengineering Cunningham, Brian; University of Illinois at Urbana-Champaign, Dept of Electrical and Computer Engineering

Smartphone Clip-On Instrument and Microfluidic Processor for Rapid Sample-to-Answer Detection of Zika Virus in Whole Blood Using Spatial RT-LAMP

Aaron M. Jankelow^{a,b,1}, Hankeun Lee^{b,c,1}, Weijing Wang^{b,c,1}, Trung-Hieu Hoang^{c,1}, Amanda Bacon^{b,c}, Fu Sun^{b,c}, Seol Chae^{b,c}, Victoria Kindratenko^{a,b}, Katherine Koprowski^{a,b}, Robert A. Stavins^d, Dylann D. Ceriani^e, Zachary W. Engelder^e, William P. King^{b,d}, Minh N. Do^c, Rashid Bashir^{a,b,c,d,f}, Enrique Valera^{a,b,*}, Brian T. Cunningham^{a,b,c,f,*}.

^a Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

^b Nick Holonyak Jr. Micro and Nanotechnology Lab, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

^c Department of Electrical and Computer Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

^d Department of Mechanical Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

^e Gener8, LLC, Carlsbad, CA 92011, USA.

^f Center for Genomic Diagnostics, Woese Institute for Genomic Biology, Urbana, IL 61801, USA.

¹ Authors contributed equally.

* Corresponding authors: E.V. (evalerac@illinois.edu), B.T.C. (bcunning@illinois.edu).

Abstract

Rapid, simple, inexpensive, accurate and sensitive point-of-care (POC) detection of viral pathogens in bodily fluids is a vital component of controlling the spread of infectious diseases. The predominant laboratory-based methods for sample processing and nucleic acid detection face limitations that prevent them from gaining wide adoption for POC applications in low resource settings and self-testing scenarios. Here, we report the design and characterization of an integrated system for rapid sample-to-answer detection of a viral pathogen in a droplet of whole blood comprised of a 2-stage microfluidic cartridge for sample processing and nucleic acid amplification, and a clip-on detection instrument that interfaces with the image sensor of a smartphone. The cartridge is designed to release viral RNA from Zika virus in whole blood using chemical lysis, followed by mixing with the assay buffer for performing reverse-transcriptase loop mediated isothermal amplification (RT-LAMP) reactions in six parallel microfluidic compartments. The battery-powered handheld detection instrument uniformly heats the compartments from below, and an array of LEDs illuminates from above, while the generation of fluorescent reporters in the compartments is kinetically monitored by collecting a series of smartphone images. We characterize the assay time and detection limits for detecting Zika RNA and gamma ray-deactivated Zika virus spiked into buffer and whole blood and compare the performance of the same assay when conducted in conventional PCR tubes. Our approach for kinetic monitoring of the fluorescence-generating process in the microfluidic compartments enables spatial analysis of early fluorescent “bloom” events for positive samples, in an approach called “Spatial LAMP” (S-LAMP). We show that S-LAMP image analysis reduces the time required to designate an assay as a positive test, compared to conventional analysis of the average fluorescent intensity of the entire compartment. S-LAMP enables the RT-LAMP process to be as short as 22 minutes, resulting in a total sample-to-answer time in the range 17-32 minutes to distinguish positive from negative samples, while demonstrating a viral RNA detection as low as 2.70×10^2 copies/ μl , and a gamma-irradiated virus of 10^3 virus particles in a single 12.5 μl droplet blood sample.

1. Introduction

Zika virus (ZIKV) is a flavivirus that was first isolated in Uganda, Africa in 1947 and is known to cause fetal microcephaly, a developmental disorder of newborn babies that is a consequence of mothers becoming infected during early pregnancy [1-3]. ZIKV is transmitted mostly by the bites of infected *Aedes aegypti* mosquitos, but sexual, perinatal, and blood-transfusion transmission have also been documented [4-9]. Although its presence was of little concern at first as the virus spread sporadically within the countries of continental South America and Asia, the 2015 ZIKV epidemic in Brazil

1
2
3 progressed quickly, raising global awareness of the infectious disease, leading to a declaration of global
4 health emergency by the World Health Organization in early 2016 [10]. Now, ZIKV has become one of
5 the neurotropic viruses that circulate in more than 87 countries, still actively infecting thousands of people
6 annually [11]. In 2020, a total of 22,923 cases were reported worldwide among which 18,941 cases were
7 from Brazil and 2,215 cases were from countries in Central America [12]. Given the wealth of
8 evidence indicating the apparent danger posed by the ZIKV, immediate action must be taken to stop the
9 propagation of the virus and to prevent future outbreaks.
10

11 Controlling and monitoring ZIKV and other insect-borne viral pathogens has been particularly
12 challenging since most infection cases are asymptomatic, while even the symptomatic infections have
13 been reported to show non-specific acute febrile illness with symptoms that are identical to that of other
14 common viral infections such as Dengue virus and Chikungunya virus [13-15]. All these viruses result in
15 diseases that present clinically with similar symptoms, including fever, fatigue, headache, rash, arthralgia,
16 myalgia, and conjunctivitis [16]. As a result of these characteristics, viral containment and early detection
17 has been especially difficult in underdeveloped countries where limited access to testing facilities,
18 shortage of trained personnel, and under-funded medical infrastructures have hindered patients from
19 receiving a proper diagnosis and prompt effective treatment. This disproportionate distribution of the
20 burden of infectious diseases is most prominent in the poorest countries and regions, motivating the
21 development of more portable and cost-effective POC diagnosing tools for viral detection that can
22 provide equivalent sensitivity and accuracy as conventional laboratory-based methods [17].
23
24

25 Various technologies are currently available for ZIKV detection but have limitations that hinder their
26 application to POC scenarios. The gold standard molecular testing method, quantitative reverse
27 transcription PCR (RT-qPCR) has been extensively exploited to detect the presence of genomic contents
28 of ZIKV through the utilization of the reverse transcriptase enzyme to amplify viral RNA copies from
29 patient samples, including blood [18, 19], urine [20-22], saliva [20], semen [23, 24], and amniotic fluid
30 [25]. Although PCR-based nucleic acid amplification provides detection limits as low as 190 copies/ul
31 when detecting extracted ZIKA RNA spiked in whole blood [26], the assays require sample preparation
32 and instruments in laboratory settings, using protocols that require benchtop instrumentation, highly
33 trained personnel to perform sample purification, viral isolation, complex genome extractions, and
34 interpretation of complex time-resolved calibration curves [27]. Moreover, due to the necessity for precise
35 thermal control, the acquisition of bulky and/or expensive equipment is not optional, making the method
36 unsuitable for POC testing [28-32]. An alternative to nucleic acid testing is enzyme-linked
37 immunosorbent assay (ELISA), which detects viral proteins, such as antigens or antibodies. Recognized
38 as being sensitive and robust, ELISA has been used in several studies for detecting low concentrations of
39 Zika-specific proteins [33, 34]. However, ELISA also requires benchtop instrumentation, complex
40 workflow, and suffers from cross-reactivity, long sample-to-answer time (~ 4h.), washing steps, and
41 stringent sample preparation procedures, resulting in an assay that is difficult to deploy in resource-
42 limited environments. Further, the antibody reagents for ELISA require careful handling and strict storage
43 conditions to preserve their function against denaturation and aggregation [35].
44
45

46 For these reasons, nucleic acid tests using isothermal amplification such as Loop-Mediated
47 Isothermal Amplification (LAMP) have recently generated significant attention for virus detection due to
48 the simplicity of assay preparation (single step) and the ease of translation to POC devices. LAMP
49 circumvents the need for thermal cycling by executing enzymatic amplification at a constant temperature,
50 which results in simplification of the assay protocol, reduction in the instrument size through removal of
51 extra circuitry for thermal control systems, and high amplification efficiency [36-42]. Compared to PCR,
52 RT-LAMP uses a larger number of primers (typically 4-6), while *Bst* DNA polymerase provides
53 increased amplification speed and yield through its superior thermal stability compared to *Taq*
54 polymerase. As a result, RT-LAMP is associated with significantly decreased the non-specific
55 amplification and enhanced resistance to interference from inhibitors in biological samples [43-46].
56
57
58
59
60

1
2
3
4 This paper describes the design and characterization of a single use, plastic, 3D printed microfluidic
5 POC diagnostic cartridge that is used in conjunction with an inexpensive, battery-powered, handheld
6 detection instrument that clips on to a smartphone to utilize its rear-facing camera as the sensor. The
7 cartridge is comprised of two stages, in which the first stage performs sample pre-processing from a
8 droplet of whole blood, while the second stage contains six separate microfluidic compartments for
9 performing independent RT-LAMP assays. The liquids in the RT-LAMP compartments are allowed to
10 spread laterally to provide a large surface area for two-dimensional image analysis of fluorescent
11 “blooms” that occur during the LAMP enzymatic amplification process when the target nucleic acid
12 sequence is present. Spatial analysis of positive LAMP amplification events (called “Spatial LAMP” (S-
13 LAMP)) allows the system to identify a positive reaction in a compartment in a shorter time, compared to
14 waiting for the entire compartment to reach a saturated fluorescent state. Reduction in the time required
15 to indicate a positive test is especially pronounced for low concentrations of the target nucleic acid
16 sequence. Importantly, the sample processing cartridge and the detection instrument are intended to
17 accurately and repeatably replicate the reagent volumes, mixing times, and temperature used in the
18 laboratory-based version of the assay.
19
20

21 In previous reports we demonstrated detection of ZIKV with an RT-LAMP assay performed in
22 narrow, low-volume silicon microfluidic channels that required a syringe pump to precisely control flow
23 rates and tubing connections to transport fluids [47]. In this work, the microfluidic cartridge is designed
24 for precise metering of the volumes of the blood, lysis buffer, and assay buffer. All fluid manipulation is
25 performed through a sliding valve manifold with pneumatic pressure supplied by manual rotation of a
26 threaded screw with a spiral-shaped microfluidic cavity. All functions of the cartridge are performed
27 manually, without the need for external power or complementary devices. The detection instrument is
28 intended to facilitate simple clip-on interfacing with mobile computing devices such as smartphones and
29 tablets with a rear-facing camera. The instrument utilizes battery power to operate an array of LEDs to
30 uniformly illuminate the LAMP assay compartments and a thermoelectric heater to rapidly and uniformly
31 bring the liquids in the LAMP compartments to a temperature of 65°C, required for the amplification
32 reaction. The instrument also contains a fluorescence emission filter and macro lens that enables the
33 mobile device’s camera to function as a broad-area fluorescence microscope that can gather a sequence of
34 images during the LAMP process from above, while the compartments are heated from below. We share
35 measurements of the liquid volume metering repeatability provided by the cartridge and the temperature
36 uniformity provided by the heater. Through the utilization of our system, precise and repetitive LAMP
37 assay preparation can be performed
38
39

40 In this work, we characterize the performance of the LAMP assay by comparing the kinetic
41 fluorescent amplification measurements conducted in conventional PCR tubes and a laboratory-based
42 thermal cycler with the same assay performed in the microfluidic compartments measured with the
43 smartphone instrument. We initially characterize the assay (in microfluidic and PCR-tube format) using
44 the target viral RNA sequence spiked into buffer, followed by further characterization performed by
45 spiking gamma ray-deactivated Zika virus into whole blood. In summary, we demonstrate that our
46 system (cartridge and clip-on smartphone instrument) achieves a detection of 2.70×10^2 copies/ μl for viral
47 RNA spiked into buffer and a 10^3 virions/ μl for gamma irradiated Zika virus spiked into whole blood.
48 The detection limits achieved with the microfluidic-based sample handling and smartphone-based readout
49 are equivalent to performing the same assay in PCR tubes with laboratory instruments. Utilizing S-LAMP,
50 the time required for positive detection is 22 min. for the lowest detectable virus concentration, compared
51 to 31 min. using measurement of the entire microfluidic assay volume, and 39 min. for detection in a PCR
52 tube. Overall, the sample-to-answer time is 17-32 min. with the system to distinguish positive from
53 negative samples.
54
55
56
57
58
59
60

1
2
3 While the system is capable of estimating viral load with the use of calibration standards, we
4 envision the approach as a means to provide rapid POC discrimination of negative samples from positive
5 samples when viral concentrations that are above the clinically relevant threshold of pre-symptomatic
6 patients (ranging from 3×10^3 - 5.2×10^6 , mean 1.1×10^6 copies/mL) which would contribute to the early
7 detection of infection [48]. Likewise, it has been reported that in case of observed chronic infection of
8 ZIKV-FLR in C6/36 cells, the concentration of viral RNA peaks at 4×10^9 copies/mL [49]. Importantly,
9 analysis of whole blood samples rather than plasma samples may be crucial, as data has shown that Zika
10 virus RNA persisted in whole blood after it disappeared in plasma [50]. While the functions of the present
11 microfluidic cartridge are segregated between two physically separate modules, we envision integrating
12 them together into a single unit that would be inexpensively manufacturable by injection molding,
13 compared to the 3-D printing technology used to fabricate the devices in this report.
14
15

16 2. Experimental

17 2.1. Assay workflow for point of care sample pre-processing and RT-LAMP analysis.

18
19
20
21 **Fig. 1a** illustrates the workflow of the microfluidic cartridge sample processing and smartphone-
22 based readout with the clip-on instrument. The cartridge functions are comprised of two physically
23 separate modules. Module “A” performs the sample lysis and mixing with an RT-LAMP reaction mix
24 (composed of buffers, RT-LAMP primers, polymerase and reverse transcriptase enzymes), and Module
25 “B” contains six physically separated 25 μ l volume liquid compartments that are filled from separate
26 inlets. Prior to sample analysis, the cartridge is prepared by drawing the lysis buffer and LAMP reaction
27 mix through separate inlets to fill internal fluid chambers with precisely metered volumes. To initiate
28 sample analysis, a drop of unprocessed whole blood is deposited onto the sample inlet port of Module A.
29 By manually rotating the threaded screw to push and pull the combined liquids through hourglass-shaped
30 mixing channels, a 12.5 μ l portion of the blood sample is mixed with the lysis buffer for 1 minute. By
31 repositioning the sliding valve, the fluid manifold opens a path between the lysed blood and the LAMP
32 reaction mix, enabling rotation of the same threaded screw to push and pull the combined liquids through
33 the mixing channels a second time. After 1 minute of mixing all three assay components (blood, lysis
34 buffer, and RT-LAMP reaction mix) the resulting solution is drawn fully into the spiral fluid channel
35 within the threaded screw. The final action performed in Module A is to move the sliding valve to a new
36 position, so the fluid manifold connects the threaded screw fluid channel to the outlet. Rotation of the
37 threaded screw pushes the approximately 200 μ l mixed solution into the outlet reservoir. For the assays
38 reported here, the fluid is withdrawn from the outlet reservoir by pipette, and immediately injected into
39 the inlet holes of Module B, where the reactions take place and are recorded using a smartphone CCD
40 camera in real-time. Second, the prepared assay solution is evenly distributed into each 25 μ l volume
41 compartment using a pipette followed by sealing the inlet and outlet holes with a silicone-based adhesive
42 tape to prevent the evaporation of fluid during RT-LAMP heating. For characterization purposes, 75 μ l of
43 the final mixture from Module A was inserted into three individual compartments in Modul B while the
44 remaining three compartments were filled with negative controls prepared separately using whole blood
45 from healthy donors. The remaining volume from Module A was tested in a benchtop thermocycler to
46 confirm the results obtained with the device. The prepared Module B is placed inside the instrument (**Fig.**
47 **S1**) where it makes physical contact with a Peltier module for heating. Finally, the smartphone camera is
48 aligned and clipped onto the detection instrument to obtain a collection of images of the fluid
49 compartments, with the LED illumination, image collection frequency, and total acquisition time
50 controlled by an app. After image collection, the data is wirelessly transferred to an off-camera database
51 for temporal and spatial analysis by Python.
52
53
54

55 Starting with a prepared Module A with metered volumes of lysis buffer and RT-LAMP reaction mix
56 in their respective fluid channels, the sample is prepared for LAMP analysis in 10 min. Following a 4.5
57
58
59
60

1
2
3 min. for Module B to reach the target temperature of 65°C, we run the LAMP reaction for a total of 40
4 min. However, using S-LAMP, we show that only 7-22 min. of LAMP reaction time is required to
5 differentiate positive from negative tests for all concentrations tested. Therefore, the total sample-to-
6 answer time is approximately 17-32 min.
7

8 **2.2. ZIKV genomic RNA and viruses.**

9

10 Genomic RNA for Zika virus strain PRVABC59 (NR-50244), genomic RNA for Zika virus
11 strain R103451 (NR-50358), and gamma-irradiated inactivated Zika virus strain PRVABC59 (NR-
12 50547) were obtained from BEI Resources and stored at -80°C after aliquoting. The stocks were then
13 diluted to the desired concentrations in either TE buffer or whole blood.
14
15

16 **2.3. Whole blood samples.**

17

18 Human whole blood from healthy individuals was obtained from BioIVT (USA) in 10 mL K2EDTA
19 tubes. The blood was stored at 4°C and under stirring until used. Storage of blood at 4°C and under
20 stirring is standard practice to prevent blood coagulation. In the case of using patient samples, blood
21 would be injected into the device immediately after collection to prevent blood coagulation.
22

23 **2.4. RT-LAMP composition.**

24

25 All RT-LAMP assays were comprised of the following components:
26 10X isothermal amplification buffer from New England Biolabs (NEB), MgSO₄ (100 mM, NEB), betaine
27 (5 M, Sigma-Aldrich), dNTP (10mM each), Bst 2.0 WarmStart DNA Polymerase (8 U/μl, New England
28 Biolabs), WarmStart RTX reverse transcriptase (15 U/μl, NEB), Evagreen dye (25 μM, Biotium), 20
29 μg/μl of Bovine Serum Albumin (NEB). In addition to these buffer components, a primer mix was added
30 to achieve the following primer concentrations in the final reaction: F3 and B3 (0.3 μM), FIP and BIP
31 (1.8 μM), and LoopF and LoopB (0.7 μM). Primer sequences were sourced from the literature [43] to
32 target unique genes that code for the capsid protein of ZIKV, as illustrated in **Fig. S2**, and synthesized by
33 Integrated DNA Technologies (IDT). The two most outer capsid gene sequences were selected as the
34 targets of the forward primer F3 and the backward primer B3. The two most inner capsid gene sequences
35 were selected as the targets of the second primer pair, the forward inner primer FIP and backward inner
36 primer BIP. The remaining primer pair, the forward loop primer LF and backward loop primer LB, were
37 designed to target the unique sequences found in between the F3 & FIP and B3 & BIP. All LAMP
38 reagents were stored at -20°C except for betaine (stored at 4°C). Accugene molecular biology grade water
39 was used to make up the remaining volume in the reaction mix to 14 μl, then 2 μl of the sample was
40 mixed into a final reaction volume of 16 μl (7:1, reaction mix:sample ratio). For on-cartridge reactions,
41 the volume was scaled-up as needed while maintaining the 7:1 ratio.
42
43

44 **2.5. Dual module microfluidic cartridge design and fabrication by 3D printing**

45

46 The cartridge is comprised of two physically separate components: Module A for sample pre-
47 processing and Module B for LAMP reactions and assay readout. While our longer-term goal is to
48 integrate both modules into a single unit, in which the output of Module A fills the compartments in
49 Module B, keeping them separated enabled us to optimize the design of each independently, while
50 facilitating prototype fabrication by 3D printing and assay characterization. Module A consists of three
51 major elements: the cartridge body, a sliding valve manifold, and a threaded syringe. As discussed in the
52 following section, Module A is fabricated using transparent material to enable the user to visually observe
53 the location of the assay fluid during the lysing and mixing procedure. The cartridge enables the user to
54 manually perform the assay with the same volumes and homogenous mixing as the laboratory-based
55 method, while avoiding the use of external pumps or motors. A detailed schematic drawing of Module A
56
57
58
59
60

1
2
3 is shown in **Fig. 2a** and **Fig. S3**. The cartridge incorporates eight holes (0.7 mm. radius): three inlet ports
4 (for lysis buffer, LAMP reagents, and whole blood sample), two outlet ports for reagent metering (lysis
5 buffer and LAMP reagents), two vent holes, and the outlet well for the final mixed solution used for
6 LAMP amplification. All the holes have connecting channels that are extended toward the center of the
7 cartridge body at specific positions to allow a continuous flow of the fluid from inlet ports, through the
8 channels of the sliding valve, and to the outlet ports. Thus, the sliding valve serves as a fluid manifold,
9 whose lateral position connects specific inlets to specific outlets for each step of cartridge preparation and
10 sample preparation. The mixing channel utilizes an hourglass shape to alternatively compress and expand
11 the fluid, to induce chaotic advection of the solution for rapid homogenization [51]. The numbered arrows
12 represent the exact positions of the sliding valve in each step of the assay preparation where positions 1, 2,
13 and 3 are determined by the right sliding valve arrow while positions 4, 5, and 6 are determined by the left
14 sliding valve arrow. The sliding valve has a total of four channels, two of which meter the lysing buffer
15 and LAMP reagent volumes, while the others serve to connect channels across the sliding valve. The
16 metered channels reside on the far-left and far-right sides of the sliding valve (referred to as lysis buffer
17 and RT-LAMP reagent channels) and are designed to hold volumes of 12.5 μl and 175 μl respectively.
18 The metered lysis buffer is mixed with the blood sample in a 1:1 ratio. Thus, the lysed sample and RT-
19 LAMP reagent follows the 1:7 ratio as optimized for off-cartridge performance. By pushing the solution
20 through the channels until the fluid reaches the outlet ports, the proper ratio of the reagents is ensured.
21 The bottom of the sliding valve has circular grooves (1 mm wide, 3 mm inner diameter) for O-rings
22 (McMaster-Carr, IL, US) to prevent leakage at the junctions of the channels. The hand-operated 800 μl
23 hollow threaded screw is used to push and pull the solution through the mixing channel, and to push the
24 mixed solution into the Modula A outlet. To ensure correct positioning of the sliding valve for each step
25 of the cartridge preparation and sample processing, two “keys” with numbered lugs corresponding to each
26 position (1 through 6) were 3D printed. To position the sliding valve into the correct position for its
27 corresponding step, the key is simply pressed into the indicated side of the cartridge, and the length of the
28 lug pushes the sliding valve into the correct location. The sliding valve, threaded screw pump, and
29 transparent materials were utilized to enable manual operation of the cartridge functions, without the use
30 of on-board actuators, complex micromachined pumps/valves, or sensors that contribute to increased cost
31 and complexity. We also envision the potential for a simple desktop mechanical instrument that could
32 interface with an inserted cartridge to automate the processes of rotating the threaded pump and sliding
33 the valve in the correct sequence of positions. A video showing how to assemble the Module A
34 microfluidic cartridge can be viewed in **Video S1** (supplementary information).
35
36
37

38 Maintaining the proper ratio between reagents is critical for optimal RT-LAMP assay performance,
39 and with our cartridge we seek to accurately and repeatedly replicate the volumes and ratios of the
40 laboratory-based version of the assay. Five volume tests were performed with deionized (DI) water for
41 each metering channel and for the volume added to the sample inlet port of a single Module A. Results
42 are shown in **Fig. 3b-d**. The 3D-printed sliding valves yielded average volumes of 12.79 μl and 174.79 μl
43 for lysis buffer and RT-LAMP reagent metering channels, respectively. The percent errors for each
44 channel were calculated to be 2.3% and 0.1%. Moreover, the 3D-printed sliding valves showed a sample
45 recovery rate of 12.17 μl from 12.5 μl of input sample (2.61% error). Thus, all the measured volumes
46 were within our design tolerance of <5% volume error.
47

48 The body of Module B, shown in **Fig. 2b**, is 3D printed from opaque material to reduce the potential
49 for optical crosstalk between adjacent channels, and to reduce the potential for external illumination to
50 reach the image sensor. The component integrates six independent vertically oriented fluid compartments
51 (0.5 depth x 20 length x 2.5 mm width) designed to contain 25 μl of fluid. The thickness of the Module B
52 body was selected to minimize mechanical bowing of the device during the 65°C LAMP assay heating
53 process. Module B assembly includes attaching transparent biocompatible tape (ARSeal, Adhesive
54 Research) to both the top and bottom surface of the device, followed by drilling inlet/outlet holes. The
55 transparent tape allows for optical imaging of the LAMP reaction and visual inspection of bubble-free
56
57
58
59
60

1
2
3 filling. Assembled modules are stored at room temperature in a sealed container until use. A video
4 showing how to seal the Module B can be viewed in **Video S2** (supplementary information).
5

6 Both modules were designed using 3D Studio software and 3D printed by a Form2 desktop
7 stereolithography 3D printer (**Fig. 2c**). BioMed Clear resin, designated for biocompatible applications,
8 was used to print Module A at 100-micron resolution, and black resin was used to produce Module B at a
9 25-micron printing resolution. To ensure a smooth surface finish, the parts were oriented vertically on the
10 build platform. After printing, the parts were immediately washed with isopropyl alcohol to remove
11 excess resin inside the channels, ports, and through holes to prevent blockage. After an isopropyl alcohol
12 bath (10 min.), the parts were dried (room temperature, 30 min.) and put into the post-curing chamber
13 (Form Cure, FormLabs; 1 h., 60°C).
14
15

16 Fabrication of two complete sets of Module A requires approximately 12 hours of printing time (~ 8
17 hours for the cartridge body and threaded syringes, and ~ 4 hours for the sliding valves). The parts were
18 printed separately to obtain the most accurate and repeatable finished dimensions to ensure correct
19 volumes. Fabrication of three Module Bs require approximately ~ 8 hours of printing time. To avoid the
20 potential for nucleic acid contamination between tests, each Module A and Module B were only used for
21 one assay.
22

23 To assemble a complete Module A from its component parts, silicon lubricant was lightly applied to
24 the O-rings on the bottom of the sliding valve, after which the valve was inserted into the cartridge body
25 with the valve arrow pointing toward the position indicators. The threaded syringe was prepared by
26 placing the O-ring at the bottom of the plunger located at the inner center of the syringe cap and sliding it
27 into the chamber after applying silicone lubricant on the inner surface. The assembled threaded syringe
28 was inserted into the cartridge body with an additional O-ring placed in the surface junction to prevent
29 leakage. The assembled module was stored at room temperature in a sealed container until use.
30

31 **2.6. Design, fabrication, and testing of the clip-on detection instrument**

32
33

34 The detection instrument was designed to accomplish the following objectives: 1. To provide rapid,
35 uniform, and accurate heating of Module B; 2. To provide consistent intensity and uniform illumination
36 of the ~ 490 nm wavelength excitation to match the 485 nm peak absorption of the Evagreen fluorescent
37 dye; and 3. To enable collection of fluorescence emission images of all six compartments using a
38 smartphone camera in a single field of view. To achieve the desired thermal conditions (65°C +/- 1°C) in
39 each reaction chamber, a Peltier thermoelectric module was used (30 x 30 x 5.3 mm³, 5 V, 1 A, Adafruit)
40 and attached to a copper sheet (1 mm, McMaster) by applying thermal paste (IC Diamond, Innovation
41 Cooling) in between the contact surfaces. The Peltier module was mounted in the center of the lower base
42 of the instrument on a disc-shaped platform with a threaded rotating lid. The rotating lid is used to press
43 the Peltier module against Module B to achieve excellent thermal contact for repeatable heat transfer.
44 While the Peltier module presses against Module B from below, a housing with a rectangular window
45 holds Module B firmly in place from above, while exposing the reaction chambers for illumination and
46 optical imaging. Providing mechanical force around the perimeter of Module B during the LAMP heating
47 process also serves to minimize the potential for bowing of the part, which would result in loss of uniform
48 contact to the heater, thus inducing temperature variation between the fluid compartments. To verify
49 uniform heat distribution, an infrared thermal imager (FLK-TIS55, Fluke Corporation, WA, USA) was
50 used to measure the fluid temperature of each compartment of Module B (**Fig. S4a**). In addition, we
51 constructed a “test” Module B that enabled us to measure the temperature of fluid within each
52 compartment for the maximum duration of an assay (40 min.) and to measure the repeatability of the
53 temperature stabilization. The test Module B was produced by drilling holes through the transparent tape,
54 for insertion of K-Type thermocouple probes (TL0260 K-Type Thermocouple, 0.13 mm Diameter,
55 Perfect Prime, NY, USA) into each compartment followed by sealing of the holes with a gel-type super
56
57
58
59
60

1
2
3 glue (Super Glue Gel control, Loctite, Ohio, USA) to prevent fluid evaporation. The submerged
4 thermocouple probes measure the fluid temperature at 1 second intervals using a thermocouple
5 thermometer (TC0520, Thermocouple Thermometer, Perfect Prime, NY, USA) (**Fig. S4b**). The Peltier
6 module offered thermal homogeneity throughout the six compartments in Module B. As shown in **Fig 3a**,
7 the temperature of each reaction compartment reached 60°C within 4.5 min. on average and stayed under
8 66°C for the rest of the incubation time. Because an average of 4.5 min. was spent on bringing the
9 solution to the optimal temperature range, the reaction amplification time was started after this time.
10

11
12 To provide uniform illumination, we designed and fabricated a custom printed circuit board (PCB)
13 with eight 458 nm blue LEDs (XPEBBL, Cree, NC, USA) and a custom constant current LED driver
14 module. We control the circuit's applied voltage with a signal supplied by the audio (headphone) jack of
15 the smartphone, and a software app. A standard wired audio cable was used to connect the audio terminal
16 on the LED controller circuit board to the smartphone. The custom constant current LED driver module
17 ensured a consistent excitation light intensity across Module B, which was captured at 10 seconds
18 intervals and with 2 seconds illumination duration in each interval. The PCB was fitted to a mechanical
19 fixture to hold four 490 nm short-pass fluorescence emission filters (Asahi Spectra, Tokyo, Japan)
20 arranged with square symmetry. The LEDs were arranged on the PCB in a circular pattern surrounding
21 Module B and oriented downwards, so that each emission filter covers two LEDs. To verify uniform
22 excitation light illumination, images of Module B were taken without the emission filter and the light
23 intensity of each pixel was analyzed using MatLab. **Fig. S5** shows that the system achieved uniform
24 excitation illumination across the surface of Module B. Two AAA batteries provide power to the LEDs
25 and a 9 V battery powers the heater. With two AAA batteries, the system is capable of approximately 10
26 h. of image recording, sufficient for 20-30 tests. The 9V battery is capable of performing approximately
27 1.5 hours of heating.
28

29
30 Finally, the top part of the instrument houses multiple components, including a 510 nm pass filter to
31 permit only the emission wavelength to reach the smartphone image sensor, a macro lens (B00XXK4AN2,
32 12X Super Macro Lens, Techo) for close-up photography, and a clip to securely hold the smartphone. The
33 instrument weighs approximately 15 ounces and has the dimensions of $\sim 87 \times 60 \times 50 \text{ mm}^3$. Two switches
34 located in the middle layer of the instrument turn the circuitry on and off. The detailed schematic of the
35 instrument is illustrated in **Fig. S1a** while **Fig. S1b** illustrates the working principles. The components
36 used to produce the instrument are all commercially available with a total cost of $\sim \$385$.
37

38 **2.7. PathTracker app.**

39

40 We designed our own mobile software (the *PathTracker* app), to obtain images and to analyze the
41 on-cartridge experiments. The *PathTracker* app gathers and records fluorescence emission images of
42 Module B at user-determined intervals. The user-friendly interface allows the user to make manual
43 adjustments to the camera parameters, including zoom factor, focus mode, exposure time, and ISO. All
44 images are compressed into High Efficiency Image File Format (HEIF) before transfer to cloud storage
45 for offline image processing.
46

47 **2.8. On-cartridge measurement procedures**

48

49 **2.8.1. Assay preparation using Module A.** A single Module A produces 200 μl of Zika RT-LAMP
50 assay solution (175 μl RT-LAMP reagents, 12.5 μl blood sample, and 12.5 μl lysing buffer). To begin
51 cartridge preparation, the threaded syringe is rotated counterclockwise one full rotation from its fully
52 advanced position to prevent the syringe from bottoming out prematurely. Using the first tire lug, the
53 sliding valve is pushed left to align the valve arrow with the position "1" indicator. Once placed in
54 position "1", lysis buffer ($\sim 20 \mu\text{l}$) is injected through the lysis buffer port until the fluid reaches the outlet
55
56
57
58
59
60

1
2
3 port. Visual observation of excess fluid in the outlet port guarantees that the channel is completely full.
4 The sliding valve is then moved to position “2” followed by adding the whole blood sample into the
5 sample inlet port. The threaded syringe is rotated counterclockwise until the lysis buffer and whole blood
6 sample are completely drawn into the chamber. The sliding valve position is then changed to position “3”
7 for mixing the solutions (1 min.) utilizing the mixing channel. After mixing by alternating
8 clockwise/counterclockwise rotation of the syringe, the mixture is drawn back into the chamber.
9 Maintaining valve position in position “3”, RT-LAMP reaction mix is injected into the RT-LAMP
10 reaction mix port until excess fluid is observed in the outlet port. Using the second tire lug, the sliding
11 valve is aligned to position “4”. By rotating the threaded syringe counterclockwise, the metered RT-
12 LAMP reagent mix is drawn into the chamber (200 μ l mixture). The sliding valve is then moved back to
13 position “3” to thoroughly mix the solution for 1 min. After drawing the mixture back into the chamber,
14 the sliding valve is changed to position “5” to push out the final assay mixture into the sample well by
15 rotating the syringe clockwise. Once all the solution is extracted, the sliding valve is moved to position
16 “6” to mechanically seal and isolate each channel to prevent any remaining fluid from escaping the device,
17 representing the “disposal” condition for a used cartridge. A video showing how to use the Module A
18 microfluidic cartridge can be viewed in **Video S3** (supplementary information).
19
20
21

22 **2.8.2. Module B loading and amplification recording.** The output solution from Module A is
23 extracted manually by pipette and loaded into the separate reaction compartments of Module B (25 μ l per
24 compartment). A negative control test is also prepared using a separate Module A with ZIKV absent from
25 the whole blood sample. In a single recording, three compartments from Module B are filled with the
26 positive virus sample, while the remaining three compartments are filled with the negative control
27 solution. Once Module B is fully loaded, the inlet and outlet holes are sealed with transparent
28 biocompatible tape to prevent leakage or evaporation during testing. The prepared Module B is inserted
29 into the detection instrument and firmly pressed against the heater using the rotating cap. The heater is
30 preheated for at least 30 min. prior to inserting the Module B to ensure rapid temperature stabilization at
31 65°C. Immediately after Module B insertion, the *PathTracker* app is launched on the smartphone to
32 record the diagnosing sites at a pre-determined interval. Videos showing how to load the sample into
33 Module B, and how to perform amplification recording with the *PathTracker* app can be viewed in **Video**
34 **S4** and **Video S5**, respectively (supplementary information).
35
36
37

38 **2.9. Spatial RT-LAMP image analysis.**

39 Although the fluorescence formation process is continuous, our image processing module performs
40 its analysis on a discrete sequence of images with a sampling interval equal to 10 seconds. The pipeline is
41 categorized into two main functional modules: image processing and amplification analysis. The
42 overview of our image analysis is described in **Fig. 2d**. The image processing module systematically
43 performs preprocessing of images, thresholding pixels, detecting amplification clusters, and tracking
44 temporal and spatial changes of identified clusters.
45
46

47 *Preprocessing:* In the preprocessing step, all of the images are converted from RGB to gray scale,
48 taking values from the green channel only. The resulting monochromatic images have pixels with
49 intensity values ranging from 0 to 255. Next, rectangular regions of interest (ROI) covering 90 x 950
50 pixels are defined and fixed in each pre-processed image. By cropping out the corresponding ROI, a set of
51 frames are compiled together for subsequent parallel computing and analysis. In addition, the intensities
52 of all the pixels within the ROI are globally shifted by an offset to smooth out any fluctuations between
53 the frames. The sequence for global intensity adjustment is obtained by applying a Gaussian filter with
54 size 5.
55
56
57
58
59
60

Thresholding: In the thresholding stage, the threshold value τ for each ROI is determined to pinpoint the amplification clusters. The conditional equation for τ is

$$\tau = \begin{cases} m + \Delta & \lambda > 3.0 \\ M & \text{otherwise} \end{cases} \quad (\text{eq. 1})$$

where m and M denote for lower and upper global threshold values while Δ and λ denote for margin of error and growth factor, respectively. Both m and M are calculated separately from two individual sets of six consecutive frames that represent the darkest and brightest moments of a recording. The value of M is taken from the median intensity value of all the pixels confined by an ROI in the last six images of a recording where all the target nucleic acids have amplified, if any. Likewise, the value of m is taken from the median intensity value of all the pixels confined by a ROI in the darkest moment of a recording, which represent the timing where the intercalating dye has become inactivated due to the denaturation of primers as the temperature gradually increases. To account for any intensity fluctuation, 10% of the difference between M and m was added to the final lower threshold value as a margin of error Δ .

$$\Delta = 0.1(M - m) \quad (\text{eq. 2})$$

Growth factor λ decides whether the identified cluster is an active amplification of target nucleic acid or background signal, such as reflections of LEDs.

$$\lambda = M/m \quad (\text{eq. 3})$$

Detection: After thresholding, the app executes a sequence of morphological transformations, including one 7x7 opening kernel followed by one 21x21 closing kernel to remove image noises. The contour detection is then initiated to suppress all regions with its size smaller than 0.5% of a ROI area. The standard functions provided by the OpenCV library are used in our implementation.

Tracking: All remaining contours represent individual amplification clusters. These clusters not only increase in size and brightness over time but also merge with neighboring clusters as the incubation progresses. To characterize these events, an automatic tracking of clusters is performed by grouping the contours into individual sequences.

Given the information obtained from the image processing module, the amplification analysis module enables temporal and spatial characterization of clusters. Two distinct types of fluorescent intensities are mainly investigated: global and activated. The global intensity (GI) measures the normalized average fluorescent intensity of all pixels within an ROI at a given amplification time, while the activated intensity (AI) measures the normalized average fluorescent intensity of all the pixels that delineate amplified nucleic acid clusters within the ROI at a given amplification time.

3. Results and discussion

3.1. Assay characterization with gamma irradiated ZIKV in buffer and whole blood using RT-LAMP performed off-cartridge in PCR tubes.

To evaluate the performance of selected primers, off-cartridge RT-LAMP experiments were performed on a standard thermocycler (QuantStudio 3, Applied Biosystems) with various concentrations (ranging from 3×10^3 to 3×10^6 copies/ μl , and blank samples) of gamma-irradiated ZIKV strain PRVABC59 in buffer solutions. In all the experiments, standard RT-LAMP protocol was followed using pipettes to mix and transfer solutions. The amplification curves and threshold times for the experiments

1
2
3 are shown in **Fig. S6** (supplementary information). Based on the collected data, the assay can detect
4 ZIKV at concentrations $\geq 3 \times 10^3$ copies/ μl with non-nonspecific amplification (reported for 6 blank
5 samples tested) occurring after 40 minutes.
6

7 Next, off-cartridge RT-LAMP experiments were performed, under the same conditions but spiking
8 the gamma-irradiated virus into whole blood samples instead of buffer. The assay showed consistent
9 performance in both blood and buffer media. To further verify the statistical similarity, t-tests were
10 performed between the results from both buffer and whole blood samples. We found that the p-value
11 across all the concentrations were greater than 0.05, indicating no significant differences in the threshold
12 times between the two distinct types of samples. The raw data for each amplification can be found in **Fig.**
13 **S7** (supplementary information). The comparison data for amplification in blood and buffer are provided
14 in **Fig. S8** (supplementary information).
15
16

17 **3.2. Assessment of Module A lysis and mixing, using off-cartridge RT-LAMP reactions**

18

19 Module A's viral lysis and LAMP reagent mixing performance was assessed by performing the
20 sample preparation steps in Module A, followed by RT-LAMP reactions in conventional PCR tubes in a
21 thermocycler. Gamma-irradiated Zika virus was spiked to whole blood samples in concentrations ranging
22 from 3×10^3 to 3×10^6 copies/ μl ($n = 3$). These results were compared side-by-side with the previously
23 performed RT-LAMP experiments conducted completely off-cartridge. Each replicate was tested in a
24 newly fabricated Module A. Since a single Module A produced multiple 16 μl reactions, we considered
25 the whole batch to be a true positive if at least one replicate showed amplification. The final amplification
26 time was determined by averaging the time of amplified replicates.
27
28

29 Results demonstrated that the amplification times for a given concentration were consistent between
30 different Module As (**Fig. 3e-g**). There were no significant differences between the assays prepared with
31 and without Module A as the p-values were > 0.05 (0.751, 0.095, and 0.733 for 3×10^4 , 3×10^5 , and 3×10^6
32 copies/ μl , respectively) (**Fig. 3h**). Moreover, the mixing performed with Module A showed improved
33 consistency at higher concentration in terms of amplification time than the assay prepared off-cartridge
34 using pipettes and PCR tubes (**Fig. 3h**). This also demonstrates that the presence of the lubricant has no
35 significant effects on the amplification time.
36

37 **3.3. Spatial RT-LAMP assay characterization in whole blood samples using Module A, Module B,** 38 **and the *PathTracker* app.**

39

40 Finally, the full on-cartridge assay (Module A for mixing, Module B for amplification, and
41 *PathTracker* app for imaging and analysis) was characterized by determining amplification time and
42 amplification location for each reaction compartment. Two separate Module As were used to prepare the
43 experimental control groups for every concentration being tested (0, 10^3 , 3×10^3 , 6×10^3 , 3×10^4 , 3×10^4 ,
44 3×10^5 , and 3×10^6 copies/ μl). For positive samples with concentrations $\geq 6 \times 10^3$ copies/ μl , 75 μl out of 200
45 μl was extracted from each Module A, for on-cartridge reactions in Module B (25 μl for each three
46 compartments). Hence, the remaining volumes were applied to the standard thermocycler as controls to
47 evaluate the accuracy of on-cartridge testing (characterization purposes). For positive samples with
48 concentrations $\leq 3 \times 10^3$ copies/ μl , the total volume (200 μl) was extracted from each Module A, for on-
49 cartridge reactions in two Module Bs (25 μl for each three compartments). In all modules B, three
50 compartments were filled with the negative control solution. The prepared Module Bs were then loaded
51 onto the instrument, immediately followed by recording of the amplification event using the *PathTracker*
52 app. For all our experiments, the camera settings were set to an imaging interval = 10 s., 400 ISO,
53 integration time = 1 s., 4X zoom factor, and auto focus mode. Upon completion of recording, the image
54
55
56
57
58
59
60

1
2
3 analysis was performed on the collected images to calculate the amplification threshold time of each
4 reaction compartment.
5

6 **Fig. 4a-b** shows the smartphone images taken at 0, 12, 18, 24, and 30 min. of an on-cartridge Spatial
7 RT-LAMP experiment with 0, 3×10^4 , and 3×10^6 copies/ μl of gamma-irradiated ZIKV spiked in whole
8 blood sample. Videos showing the amplification events for other concentrations tested can be found in the
9 supplementary information (**Video S5**, supplementary information). Visual inspection of the images
10 reveals that, for all the concentration ranges, the nucleic acid clusters were clearly observable in more
11 than one compartment. We also observe that the time required for initial cluster formation increased as
12 the virus concentration decreased. The number of clusters also shows a decreasing trend as the virus
13 concentration is reduced. All the negative control groups (0 copies/ μl) had no signs of cluster formation
14 within 35 minutes of the incubation, indicating the high specificity of the assay when performed in the
15 cartridge. Minimal to no fluid evaporation was observed in all compartments throughout the experiment,
16 and we conclude that evaporation has no effect upon quantitative positive/negative determination of the
17 reaction. Lastly, we observe no signs of cross contamination between the compartments, indicating secure
18 isolation of compartments for multiplexing analysis.
19

20
21 Next, the amplification times of full on-cartridge reactions (Module A & B) were compared with full
22 off-cartridge results previously obtained using the standard commercial thermocycler. As **Fig. S9**
23 (supplementary information) shows, we obtain consistent amplification for all concentrations down to
24 3×10^4 copies/ μl where all replicates amplified for both on and off cartridge assays. Additionally, the on-
25 cartridge amplification results display shorter amplification threshold times with statistically significant
26 (p -values < 0.05) across all concentrations. However, for on-cartridge with 6×10^3 copies/ μl , 5 out of 6
27 replicates amplified while the off-cartridge result showed amplification on all replicates. The on-cartridge
28 assays with 10^3 and 3×10^3 copies/ μl had 1 out of 6 replicates amplify while off-cartridge assay with
29 3×10^3 copies/ μl had amplification on 1 out of 3 replicates.
30

31
32 Lastly, the performance of the global and activated intensity analyses are compared in **Fig. 4c-d**. The
33 calculated amplification times at the end of the amplification event for both GI and AI analyses are
34 compared in **Fig. 4c**. For all the concentrations tested, the amplification times obtained with the AI
35 technique were statistically lower (p -values < 0.05) than the amplification times obtained with the GI
36 technique. Importantly, all six negative controls did not amplify. Using the amplification times obtained
37 for each virus concentration and analysis technique, the calibration curves are shown in **Fig. 4d**. These
38 curves also highlight the faster amplification times obtained when using AI analysis, as well as the lower
39 variability of this technique at lower concentrations.
40

41 **3.4. Discussion**

42

43 In this study, gamma irradiated ZIKV was used as a simulant for infectious ZIKV to characterize the
44 developed POC system performance, as clinical samples or patient samples with real ZIKV are
45 challenging to obtain and will be the subject of or follow-on study with international collaborators. As can
46 be seen in **Fig. 4c-d**, the lowest ZIKV concentration detected was 10^3 copies/ μl , which roughly
47 corresponds to 1560 target gamma-irradiated viral particles molecules in each 25 μl compartment in
48 Module B. It is important to point out that several studies report that gamma-irradiation damages the
49 genetic material of a virus [52], which can affect the sensitivity of nucleic acid tests when the target RNA
50 sequence within the virus is no longer intact. This phenomenon is clearly observed in the off-cartridge
51 assays, where the lowest concentration we have detected above zero of 270 RNA copies/ μl is obtained,
52 corresponding to a gamma-irradiated virus detection limit of 3×10^3 copies/ μl . This factor of
53 approximately one order of magnitude represents the expected loss in sensitivity when testing gamma
54 irradiated viruses instead of intact live viruses. For instance, a recent study on SARS-CoV-2 (also an
55 RNA virus) showed lost sensitivity by almost an order of magnitude in PCR tests when gamma-irradiated
56
57
58
59
60

1
2
3 virus was used as the target [53]. Therefore, the sensitivity of our assay was determined not using gamma
4 irradiated virus as the target, but two different strains of ZIKV genomic RNA (**Fig. S10**, supplementary
5 information). As shown in this figure, the sensitivity improved one order of magnitude as the obtained
6 Limits of Detection (LOD) of the assays were 400 and 270 copies/ μl for PVRABC58 and R103451
7 strains, respectively. This sensitivity is similar to the other previously reported ZIKA RT-LAMP assays
8 [54]. Likewise, when comparing the amplification times obtained with genomic RNA and gamma-
9 irradiated virus, the RNA amplification times were of the same order as gamma-irradiated virus samples
10 with a concentration approximately two orders of magnitude higher (270 copies/ μl of RNA (R103451
11 strain) amplified in ~ 27 min., while $3 \times 10^4/\mu\text{l}$ of gamma-irradiated virus amplified in ~ 24 min.; targets
12 spiked in buffer and experiments performed off-cartridge).
13

14
15 As mentioned in Section 3.3, the assay solution produced by Module A was fragmented. While part
16 of the final assay solution from Module A was employed for on-chip experimentation, the rest of the
17 solution was used for side-by-side off-cartridge control. Likewise, three compartments were used as
18 negative controls in all the Modules B analyzed. This approach is utilized because, in future
19 implementations of this device, we plan to achieve multiplexing by incorporating RT-LAMP primers for
20 different viruses into each compartment, so that a single cartridge could simultaneously determine the
21 presence of up to four viruses, while utilizing the remaining two compartments for experimental controls
22 to ensure assay validity. Multiplexing via sample splitting has the unfortunate effect of increasing
23 detection limits, although the detection limits demonstrated here are expected to be suitable for clinically
24 relevant testing scenarios.
25

26
27 Regarding the analysis technique, this paper compares two methods, the analysis of the global
28 intensity and the analysis of the activated intensity using the Spatial LAMP approach. The GI resembles
29 the standard quantification method used in a conventional thermocycler where overall fluorescent
30 intensity from a micro-tube represents the amplification signal. Whereas the AI quantification method
31 detects individual amplification within ROI and computes the normalized average fluorescent intensities
32 of only the identified clusters. Using GI quantification, a compartment is considered amplified if its
33 normalized average fluorescent exceeds 20% of the intensity gap between the lower and upper global
34 threshold values (m and M). In the case of AI quantification, a compartment is considered amplified when
35 a first cluster is detected. To further increase the stability and robustness of the pipeline in detecting
36 clusters from outliers, a Savitzky-Golay filter with size 11 is applied to the results before being
37 approximated by a sigmoid function in a non-linear least-squares fashion.
38

39
40 The results from **Fig. 4c-d** demonstrate the advantages of the Spatial LAMP approach (activated
41 intensity) over the traditional global intensity method. The benefits of AI analysis increase at lower virus
42 concentrations, as greater reductions in amplification time were observed. All samples analyzed with the
43 activated intensity Spatial LAMP approach showed amplification before 20 minutes. Therefore, the AI
44 method offers faster virus detection and is especially useful for screening purposes (Yes/No detection).
45 Thus, with this method we can differentiate positive from negative samples as little as 20 min. for the
46 amplification reaction. However, the steeper slope in the calibration curve obtained using the GI method
47 highlights the greater quantification capacity of this method. The raw data from **Fig. 4c-d** can be found in
48 **Fig. S11** and **Fig. S12** (supplementary information). Likewise, the criteria used by the *PathTracker* app to
49 differentiate positive samples from negative ones can be found in the supporting information (**Results 1**).
50

51
52 Despite advances in the development of POC devices for ZIKV detection in recent decades, many
53 critical challenges remain to be addressed in the application of these devices. Recently, Faria *et al.*
54 demonstrated ZIKV viral RNA detection in the nM range using gold electrodes anchored with capture
55 DNA probes. [55] Although achieving low LOD is a powerful aspect of a system for early diagnosis and
56 controlling and monitoring infectious viruses, the measurement relies on RNA extraction and purification,
57 which mandates laboratory equipment, which subsequently increases the complexity of the workflow.
58
59
60

Likewise, the fabrication of electrodes requires cleanroom fabrication techniques, which increase the overall device cost. In another example, Afsahi et al. showed label-free detection of ZIKV (LOD = 0.45 nM) by immobilizing anti-ZIKV NS1 antibodies on the surface of a graphene electrode [56]. However, the measurements were performed in PBS or diluted serum. Other reported assays demonstrated ZIKV detection by replacing the chemical RNA extraction with thermal lysing when using serum as the sample matrix [57]. Similarly, to the previous example, this device was not capable of working with unprocessed blood as they require a centrifugation step to obtain serum. Likewise, the total assay time was 3 hours. while our device can achieve the detection of the virus in < 32 min. from sample to answer. Rong et al. developed a lateral flow immunoassay that could detect ZIKV NS1 (LOD = 0.045 ng/ml) in 20 minutes [58]. However, sensitivity was drastically reduced in serum (LOD =0.15 ng/ml) and was not shown in whole blood, meaning once again centrifugation was a necessary step beforehand thus limiting POC applications. RT-RPA has been used to detect Sars-CoV-2, another RNA virus, at 1 copy/ μ l in 15 minutes in a point-of-care device made by Liu et al [59]. However, this required a previous RNA extraction step beforehand and thus similar to previous examples is less suitable for POC applications.

In **Table 1** we compare our device to other RT-LAMP POC devices used for the detection of Zika virus. It demonstrates how we were able to achieve a fast sample-to-answer time of 32 minutes and a high level of sensitivity without the need for any purification steps. Additionally, we demonstrated our assay's performance with whole blood samples. This further simplifies the workflow since it removes the need to process blood through centrifugation or filtration to obtain plasma before running our assay.

Field-ready assay systems demand minimal to no intervention of laboratory equipment to process the sample, perform the assay, and receive results with short sample-to-answer time. In this regard, our smartphone-based microfluidic system satisfies the conditions for field employment as the total time necessary to perform a complete Spatial-LAMP assay is currently < 32 min.: 1) sample injection and mixing with reagents using Module A (5 min.); 2) loading and sealing Module B (4 min.); 3) amplification and reaction site recording (22 min.); and 4) image analysis and diagnosis (0.5 min.). The current design for Module A allows for simplified mixing and metering of the lysing buffer and reagents, and only requires minimal use of pipettes to inject prepared solution for sample treatment and transferring final mixture to Module B. This study demonstrates the precise and repeatable RT-LAMP assay preparation at low cost with minimal involvement of laboratory equipment, which makes the device suitable for POC application. The preparation time can further be reduced by physically connecting Module A and B to eliminate the manual loading and sealing of the chip. We envision that a consolidated Module would also be equipped with buffer pod reservoirs that contain reagents to establish a single-use, one-step assay system only requiring the acquisition of a whole blood sample without the utilization of centrifuges, pumps, motors, and incubators. We are actively developing injection molded versions of the cartridge and instrument, which can greatly reduce the production cost while allowing for inexpensive mass-production of the system. Lastly, this compact, portable pathogen detection system takes advantage of readily available mobile devices as the image sensor for optical measurement, data analysis, and results sharing/transmission, which renders on-site diagnosis possible in various POC settings, and integration with cloud-based telehealth systems for result interpretation, reporting to health authorities, and facilitated access to physicians for development of a treatment plan.

4. Conclusion

We have demonstrated the fast detection (< 32 min.) of Zika virus using the developed Spatial RT-LAMP approach. The activated intensity Spatial LAMP approach can differentiate positive from negative samples as quickly as 22 min. The presented point-of-care device allows for the analysis of a drop whole blood sample with minimal external intervention, as the device meters the lysing buffer and LAMP reagents and performs mixing without using external pump or pipettes. Likewise, the assay does not require RNA purification and can work with unprocessed whole blood.

1
2
3
4 Moreover, the microfluidic cartridge fabricated using 3D printing enables low-cost, rapid, and simple
5 assay preparation, making the system attractive for various POC settings. Together with broad availability
6 of smartphones and an inexpensive clip-on instrument that utilizes the rear-facing image sensor, we hope
7 to provide a cost-effective device capable of bringing pathogen diagnostics to resource-poor regions.
8

9 Likewise, the spatially separated detection compartments open the door to multiplexing capabilities.
10 Thus, soon we plan to incorporate assays for other blood-based viruses that present similar symptoms as
11 Zika virus, such as Dengue and Chikungunya. Also, we will integrate the two existing modules into a
12 single device where the mixed solution from Module A flows directly into Module B without needing to
13 pipette between two distinct devices.
14
15

16 **Authors contributions**

17
18 A.M.J, H.L, W.W. and T.-H.H. contributed equally to this work. B.T.C., E.V., R.B, M.N.D. and W.P.K
19 designed the research. A.M.J, H.L, W.W., T.-H.H., A.B., F.S., S.C., V.K., K.K., R.A.S., D.D.C. and
20 Z.W.E. performed the research. A.M.J, H.L, W.W., T.-H.H., E.V., and B.C. analyzed data. H.L, A.M.J,
21 W.W., T.-H.H., R.B., E.V., and B.T.C. wrote the paper.
22

23 **Conflicts of Interest**

24
25 There are no conflicts of interest to declare.
26

27 **ACKNOWLEDGMENTS**

28
29 The following reagents were obtained through BEI Resources, NIAID, NIH: 1) Genomic RNA from Zika
30 Virus, PRVABC59, NR-50244; 2) Genomic RNA from Zika Virus, R103451, NR-50358; 3) Zika Virus,
31 PRVABC59, Infected Cell Lysate, Gamma-Irradiated, NR-50547. The authors are grateful for financial
32 support from the National Institutes of Health (R01AI139401) and from the National Science Foundation
33 Partnership for Innovation program (PFI-TT 1919015).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Plourde, A.R. and E.M. Bloch, *A Literature Review of Zika Virus*. Emerging infectious diseases, 2016. **22**(7): p. 1185-1192.
2. Waggoner, J.J. and B.A. Pinsky, *Zika Virus: Diagnostics for an Emerging Pandemic Threat*. J Clin Microbiol, 2016. **54**(4): p. 860-7.
3. Antoniou, E., et al., *Zika Virus and the Risk of Developing Microcephaly in Infants: A Systematic Review*. International journal of environmental research and public health, 2020. **17**(11): p. 3806.
4. Chan, J.F., et al., *Zika fever and congenital Zika syndrome: An unexpected emerging arboviral disease*. J Infect, 2016. **72**(5): p. 507-24.
5. Deckard, D.T., et al., *Male-to-Male Sexual Transmission of Zika Virus--Texas, January 2016*. MMWR Morb Mortal Wkly Rep, 2016. **65**(14): p. 372-4.
6. Venturi, G., et al., *An autochthonous case of Zika due to possible sexual transmission, Florence, Italy, 2014*. Euro Surveill, 2016. **21**(8): p. 30148.
7. Foy, B.D., et al., *Probable non-vector-borne transmission of Zika virus, Colorado, USA*. Emerg Infect Dis, 2011. **17**(5): p. 880-2.
8. Besnard, M., et al., *Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014*. Euro Surveill, 2014. **19**(13).
9. Magnus, M.M., et al., *Risk of Zika virus transmission by blood donations in Brazil*. Hematology, transfusion and cell therapy, 2018. **40**(3): p. 250-254.
10. Brown, C., *Zika virus outbreaks in Asia and South America*. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2016. **188**(2): p. E34-E34.
11. Pielnaa, P., et al., *Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development*. Virology, 2020. **543**: p. 34-42.
12. Organization, P.A.H., *Cases of Zika Virus Disease by Country or Territory*. 2020.
13. Duffy, M.R., et al., *Zika virus outbreak on Yap Island, Federated States of Micronesia*. N Engl J Med, 2009. **360**(24): p. 2536-43.
14. Ladhani, S.N., et al., *Outbreak of Zika virus disease in the Americas and the association with microcephaly, congenital malformations and Guillain-Barré syndrome*. Arch Dis Child, 2016. **101**(7): p. 600-2.
15. Centers-for-Disease-Control-and-Prevention. *Zika Virus*.
16. Miller, M., et al., *What Are People Tweeting About Zika? An Exploratory Study Concerning Its Symptoms, Treatment, Transmission, and Prevention*. JMIR public health and surveillance, 2017. **3**(2): p. e38-e38.
17. Valera, E., et al., *COVID-19 Point-of-Care Diagnostics: Present and Future*. ACS Nano, 2021. **15**(5): p. 7899-7906.
18. Voermans, J.J.C., et al., *Whole-Blood Testing for Diagnosis of Acute Zika Virus Infections in Routine Diagnostic Setting*. Emerg Infect Dis, 2019. **25**(7): p. 1394-1396.
19. Bui, T.T., et al., *Development of Universal and Lineage-Specific Primer Sets for Rapid Detection of the Zika Virus (ZIKV) in Blood and Urine Samples Using One-Step Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP)*. Jpn J Infect Dis, 2020. **73**(2): p. 153-156.
20. Teoh, B.-T., et al., *A reverse transcription loop-mediated isothermal amplification for broad coverage detection of Asian and African Zika virus lineages*. BMC Infectious Diseases, 2020. **20**(1): p. 947.
21. Calvert, A.E., et al., *Rapid colorimetric detection of Zika virus from serum and urine specimens by reverse transcription loop-mediated isothermal amplification (RT-LAMP)*. PLoS One, 2017. **12**(9): p. e0185340.
22. Lamb, L.E., et al., *Rapid Detection of Zika Virus in Urine Samples and Infected Mosquitos by Reverse Transcription-Loop-Mediated Isothermal Amplification*. Sci Rep, 2018. **8**(1): p. 3803.
23. Atkinson, B., et al., *Detection of Zika Virus in Semen*. Emerging Infectious Disease journal, 2016. **22**(5): p. 940.

24. Mansuy, J.M., et al., *Zika virus in semen and spermatozoa*. The Lancet Infectious Diseases, 2016. **16**(10): p. 1106-1107.
25. Mercado, M., et al., *Zika virus detection in amniotic fluid and Zika-associated birth defects*. Am J Obstet Gynecol, 2020. **222**(6): p. 610.e1-610.e13.
26. Li, L., et al., *Development of a direct reverse-transcription quantitative PCR (dirRT-qPCR) assay for clinical Zika diagnosis*. Int J Infect Dis, 2019. **85**: p. 167-174.
27. Charrel, R.N., et al., *Background review for diagnostic test development for Zika virus infection*. Bulletin of the World Health Organization, 2016. **94**(8): p. 574-584D.
28. Zhang, C. and D. Xing, *Miniaturized PCR chips for nucleic acid amplification and analysis: latest advances and future trends*. Nucleic acids research, 2007. **35**(13): p. 4223-4237.
29. Lee, S.H., et al., *A polymer lab-on-a-chip for reverse transcription (RT)-PCR based point-of-care clinical diagnostics*. Lab Chip, 2008. **8**(12): p. 2121-7.
30. Chen, Z., et al., *A microfluidic system for saliva-based detection of infectious diseases*. Ann N Y Acad Sci, 2007. **1098**: p. 429-36.
31. Chen, D., et al., *An integrated, self-contained microfluidic cassette for isolation, amplification, and detection of nucleic acids*. Biomed Microdevices, 2010. **12**(4): p. 705-19.
32. Ahmad, F. and S.A. Hashsham, *Miniaturized nucleic acid amplification systems for rapid and point-of-care diagnostics: a review*. Anal Chim Acta, 2012. **733**: p. 1-15.
33. Mishra, N., et al., *Zika Virus Peptide ELISA (ZIKV-NS2B-Concat ELISA) for Detection of IgG Antibodies to Zika Virus Infection*. Methods Mol Biol, 2020. **2142**: p. 113-122.
34. Lee, K.H. and H. Zeng, *Aptamer-Based ELISA Assay for Highly Specific and Sensitive Detection of Zika NS1 Protein*. Analytical Chemistry, 2017. **89**(23): p. 12743-12748.
35. Alam, M.A., et al., *Diagnostic approaches for the rapid detection of Zika virus—A review*. Process Biochemistry, 2021. **101**: p. 156-168.
36. Priye, A., et al., *A smartphone-based diagnostic platform for rapid detection of Zika, chikungunya, and dengue viruses*. Scientific Reports, 2017. **7**(1): p. 44778.
37. Kurosaki, Y., et al., *Development and evaluation of a rapid molecular diagnostic test for Zika virus infection by reverse transcription loop-mediated isothermal amplification*. Scientific Reports, 2017. **7**(1): p. 13503.
38. Kong, J.E., et al., *Highly Stable and Sensitive Nucleic Acid Amplification and Cell-Phone-Based Readout*. ACS Nano, 2017. **11**(3): p. 2934-2943.
39. Ganguli, A., et al., *Rapid isothermal amplification and portable detection system for SARS-CoV-2*. Proceedings of the National Academy of Sciences, 2020. **117**(37): p. 22727-22735.
40. Sun, F., et al., *Smartphone-based multiplex 30-minute nucleic acid test of live virus from nasal swab extract*. Lab on a Chip, 2020. **20**(9): p. 1621-1627.
41. Chen, W., et al., *Mobile Platform for Multiplexed Detection and Differentiation of Disease-Specific Nucleic Acid Sequences, Using Microfluidic Loop-Mediated Isothermal Amplification and Smartphone Detection*. Analytical Chemistry, 2017. **89**(21): p. 11219-11226.
42. Damhorst, G.L., et al., *Smartphone-Imaged HIV-1 Reverse-Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) on a Chip from Whole Blood*. Engineering (Beijing), 2015. **1**(3): p. 324-335.
43. Sabalza, M., et al., *Detection of Zika virus using reverse-transcription LAMP coupled with reverse dot blot analysis in saliva*. PloS one, 2018. **13**(2): p. e0192398.
44. Sharma, S., M.A. Kabir, and W. Asghar, *Lab-on-a-Chip Zika Detection With Reverse Transcription Loop-Mediated Isothermal Amplification–Based Assay for Point-of-Care Settings*. Archives of Pathology & Laboratory Medicine, 2020. **144**(11): p. 1335-1343.
45. Dhama, K., et al., *Loop-mediated isothermal amplification of DNA (LAMP): a new diagnostic tool lights the world of diagnosis of animal and human pathogens: a review*. Pakistan journal of biological sciences : PJBS, 2014. **17**(2): p. 151-166.
46. Chen, Z., et al., *A Rapid, Self-confirming Assay for HIV: Simultaneous Detection of Anti-HIV Antibodies and Viral RNA*. Journal of AIDS & clinical research, 2016. **7**(1): p. 540.

- 1
- 2
- 3
- 4 47. Ganguli, A., et al., *Hands-free smartphone-based diagnostics for simultaneous detection of Zika, Chikungunya, and Dengue at point-of-care*. Biomedical microdevices, 2017. **19**(4): p. 1-13.
- 5
- 6 48. Musso, D., et al., *Molecular detection of Zika virus in blood and RNA load determination during the French Polynesian outbreak*. Journal of medical virology, 2017. **89**(9): p. 1505-1510.
- 7
- 8 49. Lahon, A., et al., *Characterization of a Zika Virus Isolate from Colombia*. PLoS neglected tropical diseases, 2016. **10**(9): p. e0005019-e0005019.
- 9
- 10 50. Mansuy, J.M., et al., *Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens*. Emerg Infect Dis, 2017. **23**(5): p. 863-865.
- 11
- 12 51. Mondal, B., et al., *Numerical study of mixing in wavy micromixers: comparison between raccoon and serpentine mixer*. Chemical Engineering and Processing - Process Intensification, 2019. **136**: p. 44-61.
- 13
- 14 52. Hume, A.J., et al., *Inactivation of RNA Viruses by Gamma Irradiation: A Study on Mitigating Factors*. Viruses, 2016. **8**(7).
- 15
- 16 53. Durante, M., et al., *Virus Irradiation and COVID-19 Disease*. Frontiers in Physics, 2020. **8**(415).
- 17 54. Ganguli, A., et al., *Reverse Transcription Loop-Mediated Isothermal Amplification Assay for Ultrasensitive Detection of SARS-CoV-2 in Saliva and Viral Transport Medium Clinical Samples*. Analytical Chemistry, 2021. **93**(22): p. 7797-7807.
- 18
- 19 55. Faria, H.A.M. and V. Zucolotto, *Label-free electrochemical DNA biosensor for zika virus identification*. Biosensors and Bioelectronics, 2019. **131**: p. 149-155.
- 20
- 21 56. Afsahi, S., et al., *Novel graphene-based biosensor for early detection of Zika virus infection*. Biosensors and Bioelectronics, 2018. **100**: p. 85-88.
- 22
- 23 57. Pardee, K., et al., *Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components*. Cell, 2016. **165**(5): p. 1255-1266.
- 24
- 25 58. Rong, Z., et al., *Smartphone-based fluorescent lateral flow immunoassay platform for highly sensitive point-of-care detection of Zika virus nonstructural protein 1*. Analytica Chimica Acta, 2019. **1055**: p. 140-147.
- 26
- 27 59. Liu, D., et al., *A microfluidic-integrated lateral flow recombinase polymerase amplification (MI-IF-RPA) assay for rapid COVID-19 detection*. Lab on a Chip, 2021. **21**(10): p. 2019-2026.
- 28
- 29 60. Batule, B.S., Y. Seok, and M.G. Kim, *Paper-based nucleic acid testing system for simple and early diagnosis of mosquito-borne RNA viruses from human serum*. Biosens Bioelectron, 2020. **151**: p. 111998.
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure captions

Fig. 1. Point-of-care testing workflow of the smartphone-based Spatial RT-LAMP ZIKV detection system. **1)** The patient blood droplet is collected and loaded into the inlet port of Module A; **2)** the blood is thoroughly mixed with lysing buffer and RT-LAMP reagents using the mixing channel and threaded syringe of Module A; **3)** the final assay mixture is extracted from Module A and loaded into Module B, followed by sealing of inlet and outlet holes; **4)** the prepared Module B is inserted into the detection instrument where the amplification reaction occurs, and a smartphone is locked in position using a clip to align the rear-facing camera with the instrument; **5)** Using an audio cable connection between the smartphone and the instrument (not shown in the figure), the app is initiated to take consecutive images of the reaction compartments at 10-seconds intervals, producing a collection of images that are subsequently analyzed by software.

Fig. 2. PathTracker detection concept of operation. **a)** Module A consists of three major components: cartridge body, sliding valve, and threaded syringe. The sliding valve has two metered channels to ensure the proper ratio between lysis buffer, RT-LAMP reagents, and the blood sample. The threaded syringe provides pneumatic force for mixing and fluid movement to the outlet; **b)** Module B has six separate compartments that each hold 25 μl . Transparent tape is applied to both top and bottom surfaces to seal the compartments; **c)** A photograph of the complete detection system; **d)** Spatial analysis of fluorescence generation in the fluid compartments is used to identify initial formation and growth of fluorescent blooms during the RT-LAMP, using an “activated intensity” metric to more rapidly identify a positive test. For brevity, only 3 consecutive image frames in the middle of a recording are visualized.

Fig. 3. Device characterization. **a)** Temperature characterization curve for Module B compartments in contact with the instrument heater. The gray dotted line denotes the target temperature is 65°C; **b-c)** Repeatability characterization of **b)** blood volume metering (Module A) and **c)** lysis buffer metering (Module A), with a target volume of 12.5 μl in both cases; **d)** Repeatability characterization of RT-LAMP reaction mix metering (Module A), with a target volume of 175 μl ; **e)** Bar plot showing amplification time versus Zika virus concentration spiked in whole blood. Module A mixing and off-cartridge amplification. The numbers over the bars indicate the number of amplifying replicates; **f)** the average amplification time of the results from **e)**; **g)** Normalized amplification curves of the results from **f)**; **h)** Comparison of on- and off-cartridge mixing (off-cartridge amplification).

Fig. 4. On-cartridge analysis and detection results with gamma-irradiated virus spiked in whole blood. Images taken by the smartphone are analyzed by the *PathTracker* app, which tracks fluorescence intensity and clusters of amplification; **a-b)** Smartphone images of on-cartridge amplification of **a)** 0 and 3×10^6 copies/ μl , and **b)** 0 and 3×10^4 copies/ μl of gamma-irradiated Zika virus in whole blood at $t = 0, 12, 18, 24,$ and 30 min. Images marked to indicate area of focus for each compartment in Module B; **c)** Amplification times versus concentration bar plot for global intensity and activated intensity analysis from the *PathTracker* app. T-tests performed between the two analysis types show significant differences in the two methods in all concentrations. Numbers over bars indicate how many compartments out of all tested amplified for a given concentration; **d)** Zika detection calibration curves obtained from both analysis methods.

Pre-treatment and mixing of samples	Sample	Reaction time (min)	RNA Extraction Method	Limit of detection	Reading method	Ref
Magnetic Actuation through Microfluidic Device	Plasma	50	Extraction Kit processed on-chip	100 copies/ml	Colorimetric	[44]
Automated Syringe Pump based mixing	Whole Blood	50	Chemical Lysis On-Chip	1.56×10^5 PFU/ml	Smartphone-based reader (fluorescence)	[47]
LAMP Buffer pipetted onto paper-chip after extraction	Serum	~60	Chemical Lysis, Hybridization, and Elution on-chip	10 copies/ μ l	ChemiDoc MP imaging system	[60]
Microfluidic device with metering capabilities, no pumps or motors needed	Whole Blood	32	Chemical Lysis on-chip	10^3 copies/ μ l	Smartphone-based reader (fluorescence)	This Paper

Table 1. RT-LAMP-based point-of-care devices for Zika virus detection.